Gold prices steady ahead of Fed decision, Trump’s tariff deadline
Investing.com - Merck&Co (NYSE: MRK) reported second quarter EPS of $2.13, $0.10 better than the analyst estimate of $2.03. Revenue for the quarter came in at $15.81B versus the consensus estimate of $15.87B.
Guidance
Merck&Co sees FY 2025 EPS of $8.87-$8.97 versus the analyst consensus of $8.87.
Merck&Co sees FY 2025 revenue of $64.30B-$65.30B versus the analyst consensus of $64.90B.
Merck&Co’s stock price closed at $84.06. It is up 0.96% in the last 3 months and down -27.06% in the last 12 months.
Merck&Co saw 2 positive EPS revisions and 10 negative EPS revisions in the last 90 days. See Merck&Co’s stock price’s past reactions to earnings here.
According to InvestingPro, Merck&Co’s Financial Health score is "great performance".
Check out Merck&Co’s recent earnings performance, and Merck&Co’s financials here.
Stay up-to-date on all of the upcoming earnings reports by visiting Investing.com’s earnings calendar